ABSTRACT
Purpose We previously developed an approach to calibrate computational tools for clinical variant classification, updating recommendations for the reliable use of variant impact predictors to provide evidence strength up to Strong. A new generation of tools using distinctive approaches have since been released, and these methods must be independently calibrated for clinical application.
Method Using our local posterior probability-based calibration and our established data set of ClinVar pathogenic and benign variants, we determined the strength of evidence provided by three new tools (AlphaMissense, ESM1b, VARITY) and calibrated scores meeting each evidence strength. Results
All three tools reached the Strong level of evidence for variant pathogenicity and Moderate for benignity, though sometimes for few variants. Compared to previously recommended tools, these yielded at best only modest improvements in the tradeoffs of evidence strength and false positive predictions.
Conclusion At calibrated thresholds, three new computational predictors provided evidence for variant pathogenicity at similar strength to the four previously recommended predictors (and comparable with functional assays for some variants). This calibration broadens the scope of computational tools for application in clinical variant classification. Their new approaches offer promise for future advancement of the field.
Competing Interest Statement
Leslie G. Biesecker is a member of the Illumina Medical Ethics Committee, receives research support from Merck, Inc., and royalties from Wolters-Kluwer. Vikas Pejaver and Predrag Radivojac participated in the development of some of the tools assessed in this study. Anne O'Donnell-Luria receives research support from PacBio and is a consultant for Addition Therapeutics and on the SAB for Congenica Inc.